A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer.
Cascone T, Sepesi B, Lin HY, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Mehran RJ, Rice DC, Behrens C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN Jr, Heymach JV.
Cascone T, et al. Among authors: lam vk.
Clin Cancer Res. 2020 Jul 15;26(14):3525-3536. doi: 10.1158/1078-0432.CCR-19-4180. Epub 2020 Mar 19.
Clin Cancer Res. 2020.
PMID: 32193228
Free PMC article.